X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.pharmiweb.com/press-release/2023-05-02/abivax-publication-of-an-expert-article-in-jcc-on-obefazimod-as-promising-therapeutic-management-op
https://www.accesswire.com/734108/Abivax-Publishes-Novel-Data-with-Respect-to-Obefazimods-Anti-Inflammatory-Mechanism-of-Action
https://www.accesswire.com/732594/Abivax-Receives-FDA-Agreement-on-Pediatric-Development-Plan-with-Obefazimod-in-IBD
https://www.accesswire.com/719914/First-US-Patient-Enrolled-in-Global-Phase-3-Program-with-Obefazimod-in-Ulcerative-Colitis
https://www.accesswire.com/714745/Abivax-Phase-2b-Study-Results-of-Obefazimod-ABX464-in-Ulcerative-Colitis-Published-in-the-Lancet-Gastroenterology-Hepatology
https://endpts.com/french-startup-abivax-raises-49m-to-cross-the-phiii-finish-line-for-ulcerative-colitis-drug/
Market Place
Share 
